nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—MAPK8—atopic dermatitis	0.472	1	CbGaD
Nilotinib—CYP2C8—Mometasone—atopic dermatitis	0.0222	0.0975	CbGbCtD
Nilotinib—CYP2B6—Diphenhydramine—atopic dermatitis	0.0168	0.0739	CbGbCtD
Nilotinib—ABCG2—Hydrocortisone—atopic dermatitis	0.0133	0.0584	CbGbCtD
Nilotinib—CYP2C8—Loratadine—atopic dermatitis	0.0127	0.056	CbGbCtD
Nilotinib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0119	0.0521	CbGbCtD
Nilotinib—ABCB1—Tacrolimus—atopic dermatitis	0.0118	0.0518	CbGbCtD
Nilotinib—CYP2C9—Loratadine—atopic dermatitis	0.00888	0.039	CbGbCtD
Nilotinib—CYP2C9—Diphenhydramine—atopic dermatitis	0.00888	0.039	CbGbCtD
Nilotinib—ABCB1—Loratadine—atopic dermatitis	0.00861	0.0379	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—atopic dermatitis	0.00826	0.0363	CbGbCtD
Nilotinib—CYP2D6—Loratadine—atopic dermatitis	0.00812	0.0357	CbGbCtD
Nilotinib—CYP2D6—Diphenhydramine—atopic dermatitis	0.00812	0.0357	CbGbCtD
Nilotinib—ABCB1—Methylprednisolone—atopic dermatitis	0.00788	0.0347	CbGbCtD
Nilotinib—CYP2C8—Hydrocortisone—atopic dermatitis	0.00708	0.0311	CbGbCtD
Nilotinib—CYP3A4—Tacrolimus—atopic dermatitis	0.00705	0.031	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—atopic dermatitis	0.00581	0.0256	CbGbCtD
Nilotinib—CYP3A4—Loratadine—atopic dermatitis	0.00516	0.0227	CbGbCtD
Nilotinib—ABCB1—Betamethasone—atopic dermatitis	0.00512	0.0225	CbGbCtD
Nilotinib—ABCB1—Prednisolone—atopic dermatitis	0.00505	0.0222	CbGbCtD
Nilotinib—ABCB1—Hydrocortisone—atopic dermatitis	0.00479	0.0211	CbGbCtD
Nilotinib—ABCB1—Prednisone—atopic dermatitis	0.00477	0.021	CbGbCtD
Nilotinib—CYP3A4—Methylprednisolone—atopic dermatitis	0.00472	0.0208	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—atopic dermatitis	0.0044	0.0194	CbGbCtD
Nilotinib—MAPK8—skin epidermis—atopic dermatitis	0.00397	0.0974	CbGeAlD
Nilotinib—CA6—ear—atopic dermatitis	0.00386	0.0948	CbGeAlD
Nilotinib—CA3—ear—atopic dermatitis	0.00366	0.0897	CbGeAlD
Nilotinib—CYP3A4—Triamcinolone—atopic dermatitis	0.00358	0.0157	CbGbCtD
Nilotinib—CYP2C9—Dexamethasone—atopic dermatitis	0.00307	0.0135	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—atopic dermatitis	0.00307	0.0135	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—atopic dermatitis	0.00303	0.0133	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—atopic dermatitis	0.00298	0.0131	CbGbCtD
Nilotinib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00287	0.0126	CbGbCtD
Nilotinib—CYP3A4—Prednisone—atopic dermatitis	0.00286	0.0126	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—atopic dermatitis	0.00281	0.0123	CbGbCtD
Nilotinib—MAPK8—neck—atopic dermatitis	0.0019	0.0466	CbGeAlD
Nilotinib—CYP3A4—Dexamethasone—atopic dermatitis	0.00179	0.00785	CbGbCtD
Nilotinib—KIT—skin epidermis—atopic dermatitis	0.00166	0.0407	CbGeAlD
Nilotinib—MAPK8—skin of body—atopic dermatitis	0.00123	0.0302	CbGeAlD
Nilotinib—MAPK14—neck—atopic dermatitis	0.00121	0.0296	CbGeAlD
Nilotinib—EPHB2—head—atopic dermatitis	0.001	0.0246	CbGeAlD
Nilotinib—EPHA8—head—atopic dermatitis	0.000963	0.0236	CbGeAlD
Nilotinib—MAPK11—head—atopic dermatitis	0.000895	0.022	CbGeAlD
Nilotinib—CDC42BPB—head—atopic dermatitis	0.000888	0.0218	CbGeAlD
Nilotinib—EPHA3—head—atopic dermatitis	0.000841	0.0206	CbGeAlD
Nilotinib—MAPK8—head—atopic dermatitis	0.000803	0.0197	CbGeAlD
Nilotinib—EPHA6—head—atopic dermatitis	0.000803	0.0197	CbGeAlD
Nilotinib—KIT—neck—atopic dermatitis	0.000793	0.0195	CbGeAlD
Nilotinib—MAPK14—skin of body—atopic dermatitis	0.000781	0.0192	CbGeAlD
Nilotinib—PDGFRB—neck—atopic dermatitis	0.000775	0.019	CbGeAlD
Nilotinib—LYN—head—atopic dermatitis	0.000741	0.0182	CbGeAlD
Nilotinib—TIE1—head—atopic dermatitis	0.000696	0.0171	CbGeAlD
Nilotinib—EPHB6—skin of body—atopic dermatitis	0.000677	0.0166	CbGeAlD
Nilotinib—EPHB3—head—atopic dermatitis	0.000662	0.0162	CbGeAlD
Nilotinib—HCK—head—atopic dermatitis	0.000608	0.0149	CbGeAlD
Nilotinib—CA6—head—atopic dermatitis	0.000577	0.0142	CbGeAlD
Nilotinib—CA4—neck—atopic dermatitis	0.000567	0.0139	CbGeAlD
Nilotinib—CSF1R—skin of body—atopic dermatitis	0.000565	0.0139	CbGeAlD
Nilotinib—EPHA4—head—atopic dermatitis	0.000553	0.0136	CbGeAlD
Nilotinib—CA3—head—atopic dermatitis	0.000546	0.0134	CbGeAlD
Nilotinib—KIT—skin of body—atopic dermatitis	0.000513	0.0126	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Desonide—atopic dermatitis	0.000511	0.188	CbGdCrCtD
Nilotinib—MAPK14—head—atopic dermatitis	0.00051	0.0125	CbGeAlD
Nilotinib—FGR—head—atopic dermatitis	0.000508	0.0125	CbGeAlD
Nilotinib—PDGFRB—skin of body—atopic dermatitis	0.000501	0.0123	CbGeAlD
Nilotinib—EPHA2—head—atopic dermatitis	0.000474	0.0116	CbGeAlD
Nilotinib—CA2—neck—atopic dermatitis	0.00047	0.0115	CbGeAlD
Nilotinib—TEK—head—atopic dermatitis	0.000463	0.0113	CbGeAlD
Nilotinib—ABL1—skin of body—atopic dermatitis	0.000447	0.011	CbGeAlD
Nilotinib—EPHB6—head—atopic dermatitis	0.000442	0.0108	CbGeAlD
Nilotinib—PDGFRA—head—atopic dermatitis	0.000419	0.0103	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Fluocinonide—atopic dermatitis	0.000409	0.15	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Fluocinolone Acetonide—atopic dermatitis	0.000398	0.146	CbGdCrCtD
Nilotinib—CA12—head—atopic dermatitis	0.000387	0.00949	CbGeAlD
Nilotinib—MAP2K5—head—atopic dermatitis	0.000378	0.00927	CbGeAlD
Nilotinib—CSF1R—head—atopic dermatitis	0.000369	0.00905	CbGeAlD
Nilotinib—KIT—head—atopic dermatitis	0.000335	0.00822	CbGeAlD
Nilotinib—PDGFRB—head—atopic dermatitis	0.000327	0.00803	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Mometasone—atopic dermatitis	0.000317	0.117	CbGdCrCtD
Nilotinib—CA1—head—atopic dermatitis	0.000306	0.00752	CbGeAlD
Nilotinib—CA2—skin of body—atopic dermatitis	0.000304	0.00747	CbGeAlD
Nilotinib—ABL1—head—atopic dermatitis	0.000292	0.00716	CbGeAlD
Nilotinib—CYP2B6—skin of body—atopic dermatitis	0.00026	0.00638	CbGeAlD
Nilotinib—CA4—head—atopic dermatitis	0.000239	0.00588	CbGeAlD
Nilotinib—CA2—head—atopic dermatitis	0.000199	0.00487	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Methylprednisolone—atopic dermatitis	0.000189	0.0696	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—atopic dermatitis	0.000186	0.0685	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—atopic dermatitis	0.000186	0.0685	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—atopic dermatitis	0.000182	0.067	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisone—atopic dermatitis	0.000173	0.0635	CbGdCrCtD
Nilotinib—CYP2B6—head—atopic dermatitis	0.00017	0.00416	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Prednisolone—atopic dermatitis	0.000169	0.062	CbGdCrCtD
Nilotinib—CYP2D6—head—atopic dermatitis	0.000126	0.00309	CbGeAlD
Nilotinib—ABCB1—head—atopic dermatitis	9.07e-05	0.00222	CbGeAlD
Nilotinib—Discomfort—Hydrocortisone—atopic dermatitis	4.15e-05	0.000268	CcSEcCtD
Nilotinib—Connective tissue disorder—Prednisone—atopic dermatitis	4.14e-05	0.000267	CcSEcCtD
Nilotinib—Oedema—Prednisolone—atopic dermatitis	4.12e-05	0.000266	CcSEcCtD
Nilotinib—Vomiting—Tacrolimus—atopic dermatitis	4.1e-05	0.000265	CcSEcCtD
Nilotinib—Loss of consciousness—Triamcinolone—atopic dermatitis	4.08e-05	0.000263	CcSEcCtD
Nilotinib—Loss of consciousness—Methylprednisolone—atopic dermatitis	4.07e-05	0.000263	CcSEcCtD
Nilotinib—Rash—Tacrolimus—atopic dermatitis	4.07e-05	0.000263	CcSEcCtD
Nilotinib—Dermatitis—Tacrolimus—atopic dermatitis	4.06e-05	0.000262	CcSEcCtD
Nilotinib—Shock—Prednisolone—atopic dermatitis	4.05e-05	0.000262	CcSEcCtD
Nilotinib—Cough—Triamcinolone—atopic dermatitis	4.05e-05	0.000261	CcSEcCtD
Nilotinib—Headache—Tacrolimus—atopic dermatitis	4.04e-05	0.000261	CcSEcCtD
Nilotinib—Oedema—Hydrocortisone—atopic dermatitis	4.02e-05	0.00026	CcSEcCtD
Nilotinib—Tachycardia—Prednisolone—atopic dermatitis	4.02e-05	0.00026	CcSEcCtD
Nilotinib—Hypertension—Triamcinolone—atopic dermatitis	4.01e-05	0.000259	CcSEcCtD
Nilotinib—Hypertension—Methylprednisolone—atopic dermatitis	4e-05	0.000258	CcSEcCtD
Nilotinib—Infection—Hydrocortisone—atopic dermatitis	4e-05	0.000258	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisolone—atopic dermatitis	3.98e-05	0.000257	CcSEcCtD
Nilotinib—Shock—Hydrocortisone—atopic dermatitis	3.96e-05	0.000256	CcSEcCtD
Nilotinib—Myalgia—Triamcinolone—atopic dermatitis	3.95e-05	0.000255	CcSEcCtD
Nilotinib—Nervous system disorder—Hydrocortisone—atopic dermatitis	3.95e-05	0.000255	CcSEcCtD
Nilotinib—Myalgia—Methylprednisolone—atopic dermatitis	3.94e-05	0.000255	CcSEcCtD
Nilotinib—Arthralgia—Methylprednisolone—atopic dermatitis	3.94e-05	0.000255	CcSEcCtD
Nilotinib—Eye disorder—Prednisone—atopic dermatitis	3.94e-05	0.000254	CcSEcCtD
Nilotinib—Anxiety—Methylprednisolone—atopic dermatitis	3.93e-05	0.000254	CcSEcCtD
Nilotinib—Tachycardia—Hydrocortisone—atopic dermatitis	3.93e-05	0.000253	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	3.92e-05	0.000253	CcSEcCtD
Nilotinib—Flushing—Prednisone—atopic dermatitis	3.91e-05	0.000252	CcSEcCtD
Nilotinib—Skin disorder—Hydrocortisone—atopic dermatitis	3.91e-05	0.000252	CcSEcCtD
Nilotinib—Ill-defined disorder—Dexamethasone—atopic dermatitis	3.91e-05	0.000252	CcSEcCtD
Nilotinib—Ill-defined disorder—Betamethasone—atopic dermatitis	3.91e-05	0.000252	CcSEcCtD
Nilotinib—Discomfort—Triamcinolone—atopic dermatitis	3.91e-05	0.000252	CcSEcCtD
Nilotinib—Discomfort—Methylprednisolone—atopic dermatitis	3.9e-05	0.000251	CcSEcCtD
Nilotinib—Hyperhidrosis—Hydrocortisone—atopic dermatitis	3.89e-05	0.000251	CcSEcCtD
Nilotinib—Dry mouth—Triamcinolone—atopic dermatitis	3.87e-05	0.00025	CcSEcCtD
Nilotinib—Anorexia—Hydrocortisone—atopic dermatitis	3.84e-05	0.000248	CcSEcCtD
Nilotinib—Nausea—Tacrolimus—atopic dermatitis	3.83e-05	0.000247	CcSEcCtD
Nilotinib—Angiopathy—Prednisone—atopic dermatitis	3.82e-05	0.000247	CcSEcCtD
Nilotinib—Confusional state—Methylprednisolone—atopic dermatitis	3.81e-05	0.000246	CcSEcCtD
Nilotinib—Immune system disorder—Prednisone—atopic dermatitis	3.81e-05	0.000246	CcSEcCtD
Nilotinib—Malaise—Betamethasone—atopic dermatitis	3.8e-05	0.000245	CcSEcCtD
Nilotinib—Malaise—Dexamethasone—atopic dermatitis	3.8e-05	0.000245	CcSEcCtD
Nilotinib—Oedema—Triamcinolone—atopic dermatitis	3.79e-05	0.000245	CcSEcCtD
Nilotinib—Vertigo—Betamethasone—atopic dermatitis	3.78e-05	0.000244	CcSEcCtD
Nilotinib—Vertigo—Dexamethasone—atopic dermatitis	3.78e-05	0.000244	CcSEcCtD
Nilotinib—Syncope—Betamethasone—atopic dermatitis	3.78e-05	0.000244	CcSEcCtD
Nilotinib—Syncope—Dexamethasone—atopic dermatitis	3.78e-05	0.000244	CcSEcCtD
Nilotinib—Arrhythmia—Prednisone—atopic dermatitis	3.76e-05	0.000243	CcSEcCtD
Nilotinib—Infection—Triamcinolone—atopic dermatitis	3.76e-05	0.000243	CcSEcCtD
Nilotinib—Hypotension—Hydrocortisone—atopic dermatitis	3.76e-05	0.000243	CcSEcCtD
Nilotinib—Infection—Methylprednisolone—atopic dermatitis	3.76e-05	0.000242	CcSEcCtD
Nilotinib—Shock—Triamcinolone—atopic dermatitis	3.73e-05	0.000241	CcSEcCtD
Nilotinib—Insomnia—Prednisolone—atopic dermatitis	3.73e-05	0.000241	CcSEcCtD
Nilotinib—Alopecia—Prednisone—atopic dermatitis	3.72e-05	0.00024	CcSEcCtD
Nilotinib—Shock—Methylprednisolone—atopic dermatitis	3.72e-05	0.00024	CcSEcCtD
Nilotinib—Nervous system disorder—Methylprednisolone—atopic dermatitis	3.71e-05	0.000239	CcSEcCtD
Nilotinib—Loss of consciousness—Betamethasone—atopic dermatitis	3.7e-05	0.000239	CcSEcCtD
Nilotinib—Loss of consciousness—Dexamethasone—atopic dermatitis	3.7e-05	0.000239	CcSEcCtD
Nilotinib—Paraesthesia—Prednisolone—atopic dermatitis	3.7e-05	0.000239	CcSEcCtD
Nilotinib—Tachycardia—Triamcinolone—atopic dermatitis	3.7e-05	0.000239	CcSEcCtD
Nilotinib—Mental disorder—Prednisone—atopic dermatitis	3.69e-05	0.000238	CcSEcCtD
Nilotinib—Tachycardia—Methylprednisolone—atopic dermatitis	3.69e-05	0.000238	CcSEcCtD
Nilotinib—Skin disorder—Methylprednisolone—atopic dermatitis	3.67e-05	0.000237	CcSEcCtD
Nilotinib—Erythema—Prednisone—atopic dermatitis	3.67e-05	0.000237	CcSEcCtD
Nilotinib—Malnutrition—Prednisone—atopic dermatitis	3.67e-05	0.000237	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	3.67e-05	0.000237	CcSEcCtD
Nilotinib—Hyperhidrosis—Triamcinolone—atopic dermatitis	3.66e-05	0.000236	CcSEcCtD
Nilotinib—Hyperhidrosis—Methylprednisolone—atopic dermatitis	3.65e-05	0.000236	CcSEcCtD
Nilotinib—Insomnia—Hydrocortisone—atopic dermatitis	3.64e-05	0.000235	CcSEcCtD
Nilotinib—Hypertension—Dexamethasone—atopic dermatitis	3.64e-05	0.000235	CcSEcCtD
Nilotinib—Hypertension—Betamethasone—atopic dermatitis	3.64e-05	0.000235	CcSEcCtD
Nilotinib—Paraesthesia—Hydrocortisone—atopic dermatitis	3.61e-05	0.000233	CcSEcCtD
Nilotinib—Myalgia—Dexamethasone—atopic dermatitis	3.59e-05	0.000231	CcSEcCtD
Nilotinib—Myalgia—Betamethasone—atopic dermatitis	3.59e-05	0.000231	CcSEcCtD
Nilotinib—Anxiety—Dexamethasone—atopic dermatitis	3.57e-05	0.000231	CcSEcCtD
Nilotinib—Anxiety—Betamethasone—atopic dermatitis	3.57e-05	0.000231	CcSEcCtD
Nilotinib—Discomfort—Betamethasone—atopic dermatitis	3.54e-05	0.000229	CcSEcCtD
Nilotinib—Discomfort—Dexamethasone—atopic dermatitis	3.54e-05	0.000229	CcSEcCtD
Nilotinib—Dyspepsia—Hydrocortisone—atopic dermatitis	3.54e-05	0.000229	CcSEcCtD
Nilotinib—Hypotension—Methylprednisolone—atopic dermatitis	3.53e-05	0.000228	CcSEcCtD
Nilotinib—Pain—Prednisolone—atopic dermatitis	3.52e-05	0.000227	CcSEcCtD
Nilotinib—Decreased appetite—Hydrocortisone—atopic dermatitis	3.5e-05	0.000226	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	3.47e-05	0.000224	CcSEcCtD
Nilotinib—Fatigue—Hydrocortisone—atopic dermatitis	3.47e-05	0.000224	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—atopic dermatitis	3.46e-05	0.000223	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	3.45e-05	0.000223	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	3.44e-05	0.000222	CcSEcCtD
Nilotinib—Pain—Hydrocortisone—atopic dermatitis	3.44e-05	0.000222	CcSEcCtD
Nilotinib—Oedema—Betamethasone—atopic dermatitis	3.44e-05	0.000222	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—atopic dermatitis	3.44e-05	0.000222	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—atopic dermatitis	3.43e-05	0.000221	CcSEcCtD
Nilotinib—Insomnia—Methylprednisolone—atopic dermatitis	3.42e-05	0.000221	CcSEcCtD
Nilotinib—Infection—Betamethasone—atopic dermatitis	3.42e-05	0.00022	CcSEcCtD
Nilotinib—Infection—Dexamethasone—atopic dermatitis	3.42e-05	0.00022	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—atopic dermatitis	3.4e-05	0.00022	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—atopic dermatitis	3.4e-05	0.00022	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—atopic dermatitis	3.4e-05	0.000219	CcSEcCtD
Nilotinib—Paraesthesia—Methylprednisolone—atopic dermatitis	3.39e-05	0.000219	CcSEcCtD
Nilotinib—Anaemia—Prednisone—atopic dermatitis	3.39e-05	0.000219	CcSEcCtD
Nilotinib—Shock—Betamethasone—atopic dermatitis	3.38e-05	0.000218	CcSEcCtD
Nilotinib—Shock—Dexamethasone—atopic dermatitis	3.38e-05	0.000218	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—atopic dermatitis	3.38e-05	0.000218	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—atopic dermatitis	3.37e-05	0.000218	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—atopic dermatitis	3.37e-05	0.000218	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—atopic dermatitis	3.37e-05	0.000217	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—atopic dermatitis	3.37e-05	0.000217	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—atopic dermatitis	3.36e-05	0.000217	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—atopic dermatitis	3.36e-05	0.000217	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—atopic dermatitis	3.34e-05	0.000215	CcSEcCtD
Nilotinib—Dyspepsia—Methylprednisolone—atopic dermatitis	3.33e-05	0.000215	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—atopic dermatitis	3.32e-05	0.000215	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—atopic dermatitis	3.32e-05	0.000215	CcSEcCtD
Nilotinib—Feeling abnormal—Hydrocortisone—atopic dermatitis	3.32e-05	0.000214	CcSEcCtD
Nilotinib—Malaise—Prednisone—atopic dermatitis	3.31e-05	0.000214	CcSEcCtD
Nilotinib—Vertigo—Prednisone—atopic dermatitis	3.3e-05	0.000213	CcSEcCtD
Nilotinib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	3.29e-05	0.000212	CcSEcCtD
Nilotinib—Syncope—Prednisone—atopic dermatitis	3.29e-05	0.000212	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—atopic dermatitis	3.28e-05	0.000212	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—atopic dermatitis	3.28e-05	0.000212	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—atopic dermatitis	3.27e-05	0.000211	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—atopic dermatitis	3.27e-05	0.000211	CcSEcCtD
Nilotinib—Fatigue—Methylprednisolone—atopic dermatitis	3.26e-05	0.00021	CcSEcCtD
Nilotinib—Pain—Triamcinolone—atopic dermatitis	3.24e-05	0.000209	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—atopic dermatitis	3.22e-05	0.000208	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—atopic dermatitis	3.21e-05	0.000207	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—atopic dermatitis	3.21e-05	0.000207	CcSEcCtD
Nilotinib—Urticaria—Hydrocortisone—atopic dermatitis	3.2e-05	0.000206	CcSEcCtD
Nilotinib—Body temperature increased—Hydrocortisone—atopic dermatitis	3.18e-05	0.000205	CcSEcCtD
Nilotinib—Abdominal pain—Hydrocortisone—atopic dermatitis	3.18e-05	0.000205	CcSEcCtD
Nilotinib—Hypertension—Prednisone—atopic dermatitis	3.17e-05	0.000204	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	3.13e-05	0.000202	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	3.13e-05	0.000202	CcSEcCtD
Nilotinib—Myalgia—Prednisone—atopic dermatitis	3.12e-05	0.000202	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—atopic dermatitis	3.12e-05	0.000202	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—atopic dermatitis	3.12e-05	0.000202	CcSEcCtD
Nilotinib—Feeling abnormal—Methylprednisolone—atopic dermatitis	3.12e-05	0.000201	CcSEcCtD
Nilotinib—Anxiety—Prednisone—atopic dermatitis	3.11e-05	0.000201	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—atopic dermatitis	3.11e-05	0.000201	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—atopic dermatitis	3.11e-05	0.000201	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	3.1e-05	0.0002	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	3.09e-05	0.0002	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—atopic dermatitis	3.09e-05	0.000199	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—atopic dermatitis	3.09e-05	0.000199	CcSEcCtD
Nilotinib—Discomfort—Prednisone—atopic dermatitis	3.09e-05	0.000199	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—atopic dermatitis	3.04e-05	0.000196	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—atopic dermatitis	3.03e-05	0.000195	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—atopic dermatitis	3.03e-05	0.000195	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—atopic dermatitis	3.01e-05	0.000194	CcSEcCtD
Nilotinib—Urticaria—Methylprednisolone—atopic dermatitis	3e-05	0.000194	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—atopic dermatitis	3e-05	0.000193	CcSEcCtD
Nilotinib—Oedema—Prednisone—atopic dermatitis	2.99e-05	0.000193	CcSEcCtD
Nilotinib—Abdominal pain—Methylprednisolone—atopic dermatitis	2.99e-05	0.000193	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—atopic dermatitis	2.99e-05	0.000193	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—atopic dermatitis	2.99e-05	0.000193	CcSEcCtD
Nilotinib—Infection—Prednisone—atopic dermatitis	2.97e-05	0.000192	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	2.97e-05	0.000192	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	2.97e-05	0.000192	CcSEcCtD
Nilotinib—Hypersensitivity—Hydrocortisone—atopic dermatitis	2.96e-05	0.000191	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—atopic dermatitis	2.96e-05	0.000191	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—atopic dermatitis	2.96e-05	0.000191	CcSEcCtD
Nilotinib—Shock—Prednisone—atopic dermatitis	2.95e-05	0.00019	CcSEcCtD
Nilotinib—Pain—Dexamethasone—atopic dermatitis	2.94e-05	0.00019	CcSEcCtD
Nilotinib—Pain—Betamethasone—atopic dermatitis	2.94e-05	0.00019	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—atopic dermatitis	2.94e-05	0.00019	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—atopic dermatitis	2.92e-05	0.000189	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—atopic dermatitis	2.91e-05	0.000188	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—atopic dermatitis	2.89e-05	0.000187	CcSEcCtD
Nilotinib—Asthenia—Hydrocortisone—atopic dermatitis	2.89e-05	0.000186	CcSEcCtD
Nilotinib—Anorexia—Prednisone—atopic dermatitis	2.85e-05	0.000184	CcSEcCtD
Nilotinib—Pruritus—Hydrocortisone—atopic dermatitis	2.85e-05	0.000184	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—atopic dermatitis	2.83e-05	0.000183	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—atopic dermatitis	2.83e-05	0.000183	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	2.81e-05	0.000181	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—atopic dermatitis	2.81e-05	0.000181	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—atopic dermatitis	2.79e-05	0.00018	CcSEcCtD
Nilotinib—Hypersensitivity—Methylprednisolone—atopic dermatitis	2.79e-05	0.00018	CcSEcCtD
Nilotinib—Diarrhoea—Hydrocortisone—atopic dermatitis	2.75e-05	0.000178	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—atopic dermatitis	2.73e-05	0.000176	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—atopic dermatitis	2.73e-05	0.000176	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	2.73e-05	0.000176	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—atopic dermatitis	2.72e-05	0.000176	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—atopic dermatitis	2.72e-05	0.000175	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—atopic dermatitis	2.72e-05	0.000175	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—atopic dermatitis	2.72e-05	0.000175	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—atopic dermatitis	2.72e-05	0.000175	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—atopic dermatitis	2.72e-05	0.000175	CcSEcCtD
Nilotinib—Asthenia—Methylprednisolone—atopic dermatitis	2.71e-05	0.000175	CcSEcCtD
Nilotinib—Insomnia—Prednisone—atopic dermatitis	2.71e-05	0.000175	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—atopic dermatitis	2.69e-05	0.000174	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—atopic dermatitis	2.68e-05	0.000173	CcSEcCtD
Nilotinib—Pruritus—Methylprednisolone—atopic dermatitis	2.67e-05	0.000173	CcSEcCtD
Nilotinib—Dizziness—Hydrocortisone—atopic dermatitis	2.66e-05	0.000172	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—atopic dermatitis	2.64e-05	0.00017	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—atopic dermatitis	2.6e-05	0.000168	CcSEcCtD
Nilotinib—Rash—Prednisolone—atopic dermatitis	2.6e-05	0.000168	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—atopic dermatitis	2.6e-05	0.000168	CcSEcCtD
Nilotinib—Diarrhoea—Methylprednisolone—atopic dermatitis	2.59e-05	0.000167	CcSEcCtD
Nilotinib—Fatigue—Prednisone—atopic dermatitis	2.58e-05	0.000167	CcSEcCtD
Nilotinib—Headache—Prednisolone—atopic dermatitis	2.58e-05	0.000167	CcSEcCtD
Nilotinib—Constipation—Prednisone—atopic dermatitis	2.56e-05	0.000165	CcSEcCtD
Nilotinib—Vomiting—Hydrocortisone—atopic dermatitis	2.56e-05	0.000165	CcSEcCtD
Nilotinib—Rash—Hydrocortisone—atopic dermatitis	2.54e-05	0.000164	CcSEcCtD
Nilotinib—Dermatitis—Hydrocortisone—atopic dermatitis	2.53e-05	0.000164	CcSEcCtD
Nilotinib—Headache—Hydrocortisone—atopic dermatitis	2.52e-05	0.000163	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—atopic dermatitis	2.51e-05	0.000162	CcSEcCtD
Nilotinib—Dizziness—Methylprednisolone—atopic dermatitis	2.5e-05	0.000161	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—atopic dermatitis	2.47e-05	0.000159	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—atopic dermatitis	2.47e-05	0.000159	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—atopic dermatitis	2.47e-05	0.000159	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—atopic dermatitis	2.45e-05	0.000158	CcSEcCtD
Nilotinib—Nausea—Prednisolone—atopic dermatitis	2.45e-05	0.000158	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—atopic dermatitis	2.43e-05	0.000157	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—atopic dermatitis	2.43e-05	0.000157	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—atopic dermatitis	2.41e-05	0.000155	CcSEcCtD
Nilotinib—Vomiting—Methylprednisolone—atopic dermatitis	2.4e-05	0.000155	CcSEcCtD
Nilotinib—Nausea—Hydrocortisone—atopic dermatitis	2.39e-05	0.000154	CcSEcCtD
Nilotinib—Rash—Triamcinolone—atopic dermatitis	2.39e-05	0.000154	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—atopic dermatitis	2.39e-05	0.000154	CcSEcCtD
Nilotinib—Rash—Methylprednisolone—atopic dermatitis	2.38e-05	0.000154	CcSEcCtD
Nilotinib—Dermatitis—Methylprednisolone—atopic dermatitis	2.38e-05	0.000154	CcSEcCtD
Nilotinib—Urticaria—Prednisone—atopic dermatitis	2.38e-05	0.000154	CcSEcCtD
Nilotinib—Headache—Triamcinolone—atopic dermatitis	2.37e-05	0.000153	CcSEcCtD
Nilotinib—Headache—Methylprednisolone—atopic dermatitis	2.37e-05	0.000153	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—atopic dermatitis	2.37e-05	0.000153	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—atopic dermatitis	2.37e-05	0.000153	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—atopic dermatitis	2.35e-05	0.000152	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—atopic dermatitis	2.35e-05	0.000152	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—atopic dermatitis	2.27e-05	0.000147	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—atopic dermatitis	2.27e-05	0.000147	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—atopic dermatitis	2.25e-05	0.000145	CcSEcCtD
Nilotinib—Nausea—Methylprednisolone—atopic dermatitis	2.25e-05	0.000145	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—atopic dermatitis	2.21e-05	0.000142	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—atopic dermatitis	2.19e-05	0.000141	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—atopic dermatitis	2.19e-05	0.000141	CcSEcCtD
Nilotinib—Rash—Dexamethasone—atopic dermatitis	2.17e-05	0.00014	CcSEcCtD
Nilotinib—Rash—Betamethasone—atopic dermatitis	2.17e-05	0.00014	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—atopic dermatitis	2.17e-05	0.00014	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—atopic dermatitis	2.17e-05	0.00014	CcSEcCtD
Nilotinib—Headache—Dexamethasone—atopic dermatitis	2.15e-05	0.000139	CcSEcCtD
Nilotinib—Headache—Betamethasone—atopic dermatitis	2.15e-05	0.000139	CcSEcCtD
Nilotinib—Asthenia—Prednisone—atopic dermatitis	2.15e-05	0.000139	CcSEcCtD
Nilotinib—Pruritus—Prednisone—atopic dermatitis	2.12e-05	0.000137	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—atopic dermatitis	2.05e-05	0.000132	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—atopic dermatitis	2.04e-05	0.000132	CcSEcCtD
Nilotinib—Nausea—Betamethasone—atopic dermatitis	2.04e-05	0.000132	CcSEcCtD
Nilotinib—Dizziness—Prednisone—atopic dermatitis	1.98e-05	0.000128	CcSEcCtD
Nilotinib—Vomiting—Prednisone—atopic dermatitis	1.9e-05	0.000123	CcSEcCtD
Nilotinib—Rash—Prednisone—atopic dermatitis	1.89e-05	0.000122	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—atopic dermatitis	1.89e-05	0.000122	CcSEcCtD
Nilotinib—Headache—Prednisone—atopic dermatitis	1.88e-05	0.000121	CcSEcCtD
Nilotinib—Nausea—Prednisone—atopic dermatitis	1.78e-05	0.000115	CcSEcCtD
Nilotinib—MAPK14—Immune System—IL18—atopic dermatitis	7.11e-06	6.94e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TAC1—atopic dermatitis	7.11e-06	6.93e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NPS—atopic dermatitis	7.11e-06	6.93e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—CD4—atopic dermatitis	7.07e-06	6.9e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—CD4—atopic dermatitis	7.07e-06	6.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CCR5—atopic dermatitis	7.07e-06	6.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—IL2—atopic dermatitis	7.06e-06	6.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—IL6—atopic dermatitis	7.06e-06	6.88e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—CD4—atopic dermatitis	7.05e-06	6.88e-05	CbGpPWpGaD
Nilotinib—LYN—Cytokine Signaling in Immune system—IL6—atopic dermatitis	7.03e-06	6.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD8A—atopic dermatitis	7e-06	6.83e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—CD4—atopic dermatitis	7e-06	6.82e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—MAPK8—atopic dermatitis	6.99e-06	6.82e-05	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—IL6—atopic dermatitis	6.98e-06	6.81e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCR3—atopic dermatitis	6.97e-06	6.8e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CCR5—atopic dermatitis	6.92e-06	6.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—CD4—atopic dermatitis	6.91e-06	6.74e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CASP8—atopic dermatitis	6.86e-06	6.7e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NFKBIA—atopic dermatitis	6.86e-06	6.69e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL5—atopic dermatitis	6.75e-06	6.58e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL10—atopic dermatitis	6.75e-06	6.58e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TAC1—atopic dermatitis	6.74e-06	6.57e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NPS—atopic dermatitis	6.74e-06	6.57e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GLB1—atopic dermatitis	6.63e-06	6.46e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—MAPK8—atopic dermatitis	6.61e-06	6.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL5—atopic dermatitis	6.61e-06	6.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCR3—atopic dermatitis	6.61e-06	6.45e-05	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—IL6—atopic dermatitis	6.57e-06	6.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—IL6—atopic dermatitis	6.55e-06	6.39e-05	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—IL6—atopic dermatitis	6.55e-06	6.39e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR3—atopic dermatitis	6.54e-06	6.38e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL1B—atopic dermatitis	6.53e-06	6.37e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL1B—atopic dermatitis	6.53e-06	6.37e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL1B—atopic dermatitis	6.51e-06	6.35e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL2—atopic dermatitis	6.51e-06	6.35e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL2—atopic dermatitis	6.51e-06	6.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NFKBIA—atopic dermatitis	6.49e-06	6.34e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL2—atopic dermatitis	6.49e-06	6.33e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCL5—atopic dermatitis	6.44e-06	6.28e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	6.41e-06	6.26e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL10—atopic dermatitis	6.39e-06	6.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCL5—atopic dermatitis	6.38e-06	6.22e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CCR5—atopic dermatitis	6.37e-06	6.22e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ADSL—atopic dermatitis	6.35e-06	6.2e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—MAPK8—atopic dermatitis	6.3e-06	6.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL5—atopic dermatitis	6.26e-06	6.11e-05	CbGpPWpGaD
Nilotinib—LYN—Axon guidance—IL6—atopic dermatitis	6.25e-06	6.1e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GLB1—atopic dermatitis	6.24e-06	6.09e-05	CbGpPWpGaD
Nilotinib—ABL1—Axon guidance—IL6—atopic dermatitis	6.22e-06	6.07e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GLB1—atopic dermatitis	6.19e-06	6.04e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CASP8—atopic dermatitis	6.19e-06	6.04e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NFKBIA—atopic dermatitis	6.17e-06	6.02e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—MAPK8—atopic dermatitis	6.17e-06	6.02e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL18—atopic dermatitis	6.15e-06	6e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—MAPK8—atopic dermatitis	6.14e-06	5.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—PPARA—atopic dermatitis	6.11e-06	5.96e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—IL2—atopic dermatitis	6.1e-06	5.95e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD8A—atopic dermatitis	6.06e-06	5.91e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—MAPK8—atopic dermatitis	5.99e-06	5.84e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ADSL—atopic dermatitis	5.99e-06	5.84e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—CD4—atopic dermatitis	5.97e-06	5.83e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—MAPK8—atopic dermatitis	5.97e-06	5.82e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NGF—atopic dermatitis	5.96e-06	5.82e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ADSL—atopic dermatitis	5.93e-06	5.79e-05	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—IL6—atopic dermatitis	5.93e-06	5.78e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NGF—atopic dermatitis	5.91e-06	5.76e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NFKBIA—atopic dermatitis	5.87e-06	5.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CASP8—atopic dermatitis	5.86e-06	5.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NFKBIA—atopic dermatitis	5.85e-06	5.71e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—MAPK8—atopic dermatitis	5.85e-06	5.71e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IFNG—atopic dermatitis	5.84e-06	5.69e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TAC1—atopic dermatitis	5.82e-06	5.68e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NPS—atopic dermatitis	5.82e-06	5.68e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCL5—atopic dermatitis	5.81e-06	5.67e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CCR5—atopic dermatitis	5.8e-06	5.66e-05	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—IL6—atopic dermatitis	5.76e-06	5.62e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL10—atopic dermatitis	5.75e-06	5.61e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CCR5—atopic dermatitis	5.75e-06	5.61e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—CD4—atopic dermatitis	5.73e-06	5.59e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NFKBIA—atopic dermatitis	5.73e-06	5.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCR3—atopic dermatitis	5.71e-06	5.57e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NFKBIA—atopic dermatitis	5.7e-06	5.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—IL6—atopic dermatitis	5.66e-06	5.52e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CD4—atopic dermatitis	5.64e-06	5.5e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL10—atopic dermatitis	5.63e-06	5.5e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	5.54e-06	5.41e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—TNF—atopic dermatitis	5.53e-06	5.39e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—TNF—atopic dermatitis	5.5e-06	5.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCL5—atopic dermatitis	5.5e-06	5.36e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKBIA—atopic dermatitis	5.43e-06	5.3e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL5—atopic dermatitis	5.42e-06	5.28e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NGF—atopic dermatitis	5.38e-06	5.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL10—atopic dermatitis	5.34e-06	5.21e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CASP8—atopic dermatitis	5.28e-06	5.15e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IFNG—atopic dermatitis	5.26e-06	5.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—atopic dermatitis	5.24e-06	5.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—atopic dermatitis	5.23e-06	5.11e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CCR5—atopic dermatitis	5.23e-06	5.1e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL1B—atopic dermatitis	5.21e-06	5.08e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL2—atopic dermatitis	5.19e-06	5.06e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CASP8—atopic dermatitis	5.17e-06	5.04e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—atopic dermatitis	5.15e-06	5.03e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CASP8—atopic dermatitis	5.14e-06	5.02e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CCR5—atopic dermatitis	5.11e-06	4.99e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NGF—atopic dermatitis	5.09e-06	4.97e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—atopic dermatitis	5.08e-06	4.96e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	5.08e-06	4.95e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—MAPK8—atopic dermatitis	5.06e-06	4.93e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IFNG—atopic dermatitis	4.98e-06	4.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CCR5—atopic dermatitis	4.95e-06	4.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCL5—atopic dermatitis	4.95e-06	4.83e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKBIA—atopic dermatitis	4.92e-06	4.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CASP8—atopic dermatitis	4.9e-06	4.78e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKBIA—atopic dermatitis	4.87e-06	4.75e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCL5—atopic dermatitis	4.85e-06	4.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—atopic dermatitis	4.81e-06	4.69e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—MAPK8—atopic dermatitis	4.77e-06	4.66e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—atopic dermatitis	4.72e-06	4.6e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKBIA—atopic dermatitis	4.7e-06	4.58e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL1B—atopic dermatitis	4.69e-06	4.58e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—atopic dermatitis	4.69e-06	4.58e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PPARA—atopic dermatitis	4.69e-06	4.57e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—atopic dermatitis	4.68e-06	4.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL10—atopic dermatitis	4.62e-06	4.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCL5—atopic dermatitis	4.6e-06	4.48e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	4.59e-06	4.48e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NGF—atopic dermatitis	4.59e-06	4.47e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	4.51e-06	4.4e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NGF—atopic dermatitis	4.49e-06	4.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—atopic dermatitis	4.49e-06	4.38e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—atopic dermatitis	4.47e-06	4.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR5—atopic dermatitis	4.46e-06	4.35e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—atopic dermatitis	4.46e-06	4.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL1B—atopic dermatitis	4.44e-06	4.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—atopic dermatitis	4.44e-06	4.33e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—atopic dermatitis	4.44e-06	4.33e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKBIA—atopic dermatitis	4.44e-06	4.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—atopic dermatitis	4.43e-06	4.32e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL8—atopic dermatitis	4.4e-06	4.3e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—atopic dermatitis	4.39e-06	4.29e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—atopic dermatitis	4.37e-06	4.27e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR5—atopic dermatitis	4.37e-06	4.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—atopic dermatitis	4.33e-06	4.23e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—MAPK8—atopic dermatitis	4.3e-06	4.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NGF—atopic dermatitis	4.26e-06	4.15e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—atopic dermatitis	4.24e-06	4.14e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CASP8—atopic dermatitis	4.24e-06	4.13e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—atopic dermatitis	4.23e-06	4.13e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—atopic dermatitis	4.22e-06	4.12e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—atopic dermatitis	4.22e-06	4.12e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—atopic dermatitis	4.21e-06	4.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKBIA—atopic dermatitis	4.2e-06	4.1e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL8—atopic dermatitis	4.19e-06	4.08e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—atopic dermatitis	4.16e-06	4.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—atopic dermatitis	4.14e-06	4.04e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GLB1—atopic dermatitis	4.08e-06	3.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—MAPK8—atopic dermatitis	4.07e-06	3.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—atopic dermatitis	4.02e-06	3.93e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—atopic dermatitis	4.02e-06	3.92e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL1B—atopic dermatitis	4e-06	3.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—atopic dermatitis	4e-06	3.9e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—atopic dermatitis	4e-06	3.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—atopic dermatitis	3.99e-06	3.89e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARA—atopic dermatitis	3.98e-06	3.88e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCL5—atopic dermatitis	3.97e-06	3.88e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—atopic dermatitis	3.94e-06	3.84e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—atopic dermatitis	3.92e-06	3.83e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL1B—atopic dermatitis	3.92e-06	3.82e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ADSL—atopic dermatitis	3.91e-06	3.82e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—atopic dermatitis	3.9e-06	3.81e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL1B—atopic dermatitis	3.9e-06	3.81e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—atopic dermatitis	3.9e-06	3.8e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—atopic dermatitis	3.89e-06	3.79e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—atopic dermatitis	3.83e-06	3.73e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—atopic dermatitis	3.83e-06	3.73e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—atopic dermatitis	3.81e-06	3.72e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKBIA—atopic dermatitis	3.78e-06	3.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—atopic dermatitis	3.73e-06	3.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL1B—atopic dermatitis	3.71e-06	3.62e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKBIA—atopic dermatitis	3.7e-06	3.61e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—atopic dermatitis	3.7e-06	3.61e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—MAPK8—atopic dermatitis	3.68e-06	3.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NGF—atopic dermatitis	3.68e-06	3.59e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—MAPK8—atopic dermatitis	3.67e-06	3.58e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—atopic dermatitis	3.6e-06	3.51e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—MAPK8—atopic dermatitis	3.59e-06	3.51e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—atopic dermatitis	3.58e-06	3.49e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—MAPK8—atopic dermatitis	3.58e-06	3.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKBIA—atopic dermatitis	3.51e-06	3.43e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—atopic dermatitis	3.51e-06	3.42e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—atopic dermatitis	3.48e-06	3.39e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—atopic dermatitis	3.48e-06	3.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—MAPK8—atopic dermatitis	3.41e-06	3.32e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—atopic dermatitis	3.35e-06	3.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—atopic dermatitis	3.32e-06	3.24e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—atopic dermatitis	3.23e-06	3.15e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL1B—atopic dermatitis	3.21e-06	3.13e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—atopic dermatitis	3.21e-06	3.13e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—atopic dermatitis	3.2e-06	3.12e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—atopic dermatitis	3.16e-06	3.09e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK8—atopic dermatitis	3.09e-06	3.01e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK8—atopic dermatitis	3.06e-06	2.98e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—atopic dermatitis	3.05e-06	2.97e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKBIA—atopic dermatitis	3.04e-06	2.96e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—atopic dermatitis	3.02e-06	2.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—atopic dermatitis	2.99e-06	2.92e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK8—atopic dermatitis	2.95e-06	2.87e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARA—atopic dermatitis	2.92e-06	2.84e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—atopic dermatitis	2.86e-06	2.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—atopic dermatitis	2.79e-06	2.72e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK8—atopic dermatitis	2.78e-06	2.71e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—atopic dermatitis	2.75e-06	2.68e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—atopic dermatitis	2.7e-06	2.63e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—atopic dermatitis	2.64e-06	2.58e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK8—atopic dermatitis	2.63e-06	2.57e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—atopic dermatitis	2.6e-06	2.54e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—atopic dermatitis	2.58e-06	2.52e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—atopic dermatitis	2.54e-06	2.48e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—atopic dermatitis	2.52e-06	2.46e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—atopic dermatitis	2.5e-06	2.44e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—atopic dermatitis	2.47e-06	2.41e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARA—atopic dermatitis	2.47e-06	2.41e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—atopic dermatitis	2.4e-06	2.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—atopic dermatitis	2.39e-06	2.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK8—atopic dermatitis	2.37e-06	2.32e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—atopic dermatitis	2.35e-06	2.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—atopic dermatitis	2.34e-06	2.29e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK8—atopic dermatitis	2.32e-06	2.27e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—atopic dermatitis	2.29e-06	2.24e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—atopic dermatitis	2.28e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK8—atopic dermatitis	2.2e-06	2.15e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—atopic dermatitis	2.18e-06	2.12e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—atopic dermatitis	2.16e-06	2.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—atopic dermatitis	2.16e-06	2.11e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARA—atopic dermatitis	2.15e-06	2.1e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—atopic dermatitis	2.07e-06	2.02e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARA—atopic dermatitis	2.03e-06	1.98e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARA—atopic dermatitis	2.01e-06	1.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—atopic dermatitis	1.97e-06	1.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—atopic dermatitis	1.95e-06	1.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK8—atopic dermatitis	1.9e-06	1.86e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—atopic dermatitis	1.88e-06	1.83e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—atopic dermatitis	1.78e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—atopic dermatitis	1.74e-06	1.69e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—atopic dermatitis	1.68e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—atopic dermatitis	1.52e-06	1.48e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—atopic dermatitis	1.48e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—atopic dermatitis	1.41e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARA—atopic dermatitis	1.32e-06	1.29e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—atopic dermatitis	1.22e-06	1.19e-05	CbGpPWpGaD
